Results 171 to 180 of about 15,156,730 (296)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

, 2014
Harold E Bays Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA Abstract: Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin resistance, and/or progressive loss of β-cell function.
Bays HE
core  

Dysapolipoproteinaemia Influences the Relationship Between Very Low-Density Lipoprotein Cholesterol and Intra-Pancreatic Fat Deposition in Humans. [PDF]

Nutrients
Liu Y, Skudder-Hill L, Ko J, Shamaitijiang X, Sequeira-Bisson IR, Petrov MS.   +5 more
europepmc   +1 more source

Decreased Efficiency of Very-Low-Density Lipoprotein Lipolysis Is Linked to Both Hypertriglyceridemia and Hypercholesterolemia, but It Can Be Counteracted by High-Density Lipoprotein. [PDF]

Nutrients, 2021
Wieczorek E, Ćwiklińska A, Kuchta A, Kortas-Stempak B, Gliwińska A, Jankowski M.   +5 more
europepmc   +1 more source

Very Low-Density Lipoprotein Receptor [PDF]

, 2020
openaire   +1 more source

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis

Advanced Science, EarlyView.
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji, Yan Fang, Shen Zhang, Weichen Xu, Wenyun Guo, Jing Chen, Mingrui Zhu, Congjian Wen, Siming Chen, Yuli Zhu, Huixiong Xu, Haohao Yin   +11 more
wiley   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. [PDF]

Biomolecules
Chen Y, Lei K, Liu Y, Liu J, Wei K, Guo J, Su Z.   +6 more
europepmc   +1 more source

Very low-density lipoprotein receptor increases in a liver-specific manner due to protein deficiency but does not affect fatty liver in mice. [PDF]

Sci Rep, 2021
Oshio Y, Hattori Y, Kamata H, Ozaki-Masuzawa Y, Seki A, Tsuruta Y, Takenaka A.   +6 more
europepmc   +1 more source

Yoda1‐Functionalized Nanozymes Coordinate Piezo1 Activation and Mitochondrial Protection to Reprogram the Diabetic Osteoimmune Micromilieu and Promote Vascularized Bone Repair

Advanced Science, EarlyView.
Diabetic bone defects remain a critical clinical challenge. A 3D‐printed BCPG‐MF@Y scaffold, embedding Yoda1‐functionalized manganese dioxide‐ferritin nanozymes, scavenges mtROS, suppresses the cGAS–STING pathway, and reverses cellular senescence, while Yoda1 activates Piezo1 to direct BMSCs fate to synergistically reprogram the osteoimmune ...
Qing‐Song Deng, Ang Wang, Ren Zhang, Xu‐Ran Li, Po‐Lin Liu, Shu‐Hang He, Zi‐Yin Han, Zhi‐Han Shen, Zhan‐Ying Wei, Chang‐Ru Zhang, Fei Wang, Helen Dawes, Jian Lu, Tong‐He Zhu, Jin‐Zhong Zhao, Shang‐Chun Guo, Shi‐Cong Tao   +16 more
wiley   +1 more source

Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice

, 2004
Low-density lipoprotein receptor-related protein (LRP) contributes to factor VIII (FVIII) catabolism in vivo. Besides LRP, FVIII also interacts with very low-density lipoprotein receptor (VLDLR) in vitro.
Pharmaceutics, Van Dijk, Ko Willems, Mertens, Koen, Van Vlijmen, Bart J.M., Bovenschen, Niels, Havekes, Louis M.   +5 more
core  

Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression. [PDF]

Int J Mol Sci
Winterfeldt K, Tasin FR, Sekhar V, Siddiqi SA.   +3 more
europepmc   +1 more source